Clinical Study Of Migraine Evolution

This study has been completed.

First Received: April 12, 2007 Last Updated: April 14, 2008 History of Changes

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00460005

Purpose

Understanding the speed at which migraine headaches develop is of importance to patients. Determining the proportions in which different headache pain build-up occurs, may provide health care practitioners with valuable information with which to prescribe the most appropriate treatment. Patients who experience a slow pain build-up may gain more benefit from medications which have a slow onset of effect, high tolerability and long action.

Conversely, medications with a rapid onset of effect may be of greater benefit to patients who experience rapid onset of migraine pain.

Condition	Phase
Migraine Headache	Phase IV

Study Type:	Observational
Study Design:	Prospective
Official Title:	A Multicenter Study to Determine the Clinical Characteristics of the Temporal Aspects of Migraine in a Canadian Population: Clinical Study Of Migraine Evolution (C-SOME)

Resource links provided by NLM:

Genetics Home Reference related topics: familial hemiplegic migraine

MedlinePlus related topics: Headache Migraine

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Estimated Enrollment:	250
Study Start Date:	January 2006

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subject is outpatient.
Subject has a diagnosis of migraine with/without aura according to IHS criteria, of at least 1 years duration.
Subject is able to comprehend the study procedures and to comply with study requirements.

Exclusion Criteria:

Subject has other chronic pain condition(s) not associated with migraine
Subject is unable to understand the schedule/questionnaire.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00460005

Locations

Canada, Alberta
GSK Clinical Trials Call Centre
Calgary, Alberta, Canada, T2N 2T9
Canada, British Columbia
GSK Clinical Trials Call Centre
Richmond, British Columbia, Canada, V6X 1A3
GSK Clinical Trials Call Centre
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, New Brunswick
GSK Clinical Trials Call Centre
Saint John, New Brunswick, Canada, E2L 4L2
Canada, Nova Scotia
GSK Clinical Trials Call Centre
Halifax, Nova Scotia, Canada, B3H 3A7
Canada, Ontario
GSK Clinical Trials Call Centre
Hamilton, Ontario, Canada, L8N 1Y2
GSK Clinical Trials Call Centre
Toronto, Ontario, Canada, M5S 1B6
GSK Clinical Trials Call Centre
Unionville, Ontario, Canada, L3R 0W7
Canada, Quebec
GSK Clinical Trials Call Centre
Montreal, Quebec, Canada, H3A 2B4
GSK Clinical Trials Call Centre
Longueuil, Quebec, Canada, J4L 4N5

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials, M.D.

GlaxoSmithKline

More Information

No publications provided

Study ID Numbers:	S2W106188
Study First Received:	April 12, 2007
Last Updated:	April 14, 2008
ClinicalTrials.gov Identifier:	NCT00460005 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by GlaxoSmithKline:

Migraine
headache
observational

Study placed in the following topic categories:

Signs and Symptoms
Migraine Disorders
Headache
Central Nervous System Diseases
Neurologic Manifestations

Headache Disorders, Primary
Pain
Brain Diseases
Headache Disorders

Additional relevant MeSH terms:

Signs and Symptoms
Migraine Disorders
Nervous System Diseases
Headache
Central Nervous System Diseases

Neurologic Manifestations
Headache Disorders, Primary
Pain
Brain Diseases
Headache Disorders

ClinicalTrials.gov processed this record on September 04, 2009